Device to help physicians assess the pain experienced by patients released by Medasense
Published on January 18, 2017 at 11:27 AM · No Comments
inShare
Share
Medasense Biometrics Ltd. announced today that it has received CE mark approval for its novel Pain Monitoring Device, PMD200™. This new technology is now available to help physicians objectively assess a patient’s pain in critical care situations, where patients are unable to communicate. This allows physicians to ensure pain is properly managed.
Objectively assessing how much pain an individual person is in has long been a challenge. When a patient is unable to describe their pain, it is even more of a problem. There are currently no validated objective markers of pain that are recommended for clinical use1 and this can make it difficult, especially for anaesthesia teams, to provide the right amount of pain-relief medication.
To address these challenges Medasense has developed PMD200™, a pain monitoring device based on the patented NOL™ technology that quantifies patients’ physiological response to pain. The easy-to-use system consists of a non-invasive finger probe which acquires physiological signals from four different sensors and calculates dozens of pain-related physiological parameters. This data is then analysed by artificial intelligence algorithms and converted into a single pain index, the Nociception Level (NOL™) index, where 0 = no pain and 100 = extreme pain.
http://www.news-medical.net/news/20170118/Device-to-help-physicians-assess-the-pain-experienced-by-patients-released-by-Medasense.aspx
